Lupin manufactures pharmaceuticals as a line of business. Globally, APIs, biotechnology products, and generic formulations are all developed and marketed by Lupin Limited. The firm is a worldwide leader in the Anti-TB and Cephalosporins segments and has a substantial presence in the Cardiovascular, Diabetology, Asthma, Paediatrics, and Central Nervous system markets, among others.
Financial Results:
- Lupin Ltd. reported Total Income for Q4FY23 of ₹ 4,430 Crores up from ₹ 3,883 Crore year on year, a rise of 14%.
- Total Expenses for Q4FY23 of ₹ 4,209 Crores up from ₹ 3,984 Crores year on year, rise of 6%.
- Consolidated Net Profit of ₹ 259 Crores, up from a loss of ₹ 850 Crores in the same quarter of the previous year.
- The Earnings per Share is ₹ 5.16, down 62% from ₹ -11.40 in the same quarter of the previous year.
Most Popular
Cochin Shipyard Ltd (COCHINSHIP) Q4 FY22 Earnings Concall Transcript
Cochin Shipyard Limited (NSE:COCHINSHIP) Q4 FY22 Earnings Concall dated May. 26, 2022 Corporate Participants: Madhu S Nair -- Chairman & Managing Director Jose V J -- Director Finance Analysts: Vastupal Shah
All you need to know about Antony Waste Handling Cell in one article
Can you guess the name of the company that was listed during the IPO frenzy in 2020 and is the second largest player in the Indian municipal waste management industry?
Demystifying the Leading Non-Ferrous Recycling Company of India
“Hey, how is the market doing today?” “Oh!, its falling tremendously since morning” I am sure news like these might be a common topic of discussion for you nowadays. Interestingly,